Down-regulated MiRNA 29-b as a diagnostic marker in colorectal cancer and its correlation with ETV4 and Cyclin D1 immunohistochemical expression

Abstract

BACKGROUND:

Colorectal cancer (CRC) is the most common malignant tumor of the gastrointestinal tract with unfavorable prognosis. Therefore, novel biomarkers that may be used for new diagnostic strategies and drug-targeting therapy should be developed.

OBJECTIVES:

To investigate the expression of miR-29b in CRC and its association with ETV4 and cyclin D1 expression. Moreover, the current work aims to investigate the association between them and the clinicopathological features of CRC.

METHODS:

The expression of miR-29b and ETV4 (by qRT-PCR) and ETV4 and cyclin D1 (immunohistochemistry) was investigated in 65 cases of colon cancer and surrounding healthy tissues.

RESULTS:

MiR-29b down-regulated and ETV4 and Cyclin D1 up-regulated significantly in colon cancer tissues compared to normal nearby colonic tissues. In addition, significant associations between ETV4 and cyclin D1 expressions and progressive stage and lymph node (LN) metastasis ( $P<$ 0.001 for each) were found. Furthermore, there was a negative correlation between miR-29b gene expression and ETV4 gene expression ( $r=-$ 0.298, $P<$ 0.016).

CONCLUSION:

Down-regulation of miR-29b and over-expression of ETV4 and cyclin D1 may be utilized as early diagnostic marker for development of colon cancer. ETV4 and cyclin D1 correlate with poor prognostic indicators and considered as a possible target for therapy in colon cancer.

Keywords

Colon cancer miR-29b ETV4 cyclin D1

Abbreviations

CRC	colorectal carcinoma
miRNAs	MicroRNAs
ETV4	ETS translocation variant4

1. Introduction

Colorectal cancer (CRC) is the third prevalent form of cancer and among the tumors of the gastrointestinal tract [1]. Despite the recent advances in treatment, the CRC frequency is continuously increasing. Metastasis is indicator to bad prognosis and leads to most mortalities [2]. When combined, these epidemiological characteristics call for novel biomarkers to be adopted. The identification of aberrantly expressed and functionally involved genes in CRC pathogenesis has to be a priority in the perspective of the developing novel approaches for early detection and therapy.

MicroRNAs (miRs) are a class of small, non-coding RNAs, single-strand RNA. Approximately 22 nucleotides in length regulate target gene expression by binding to the 3’ post-transcriptional untranslated region [3] and play a critical role in human cancers and other health disorders [4]. Increasing evidence has proved that by focusing on several signaling pathways, miRNAs play a significant role in controlling cancer. Additionally, there is a connection between the development of numerous human malignancies and miRNA expression profiles [5].

Three miRNAs, miR-29a, miR-29b, and miR-29c, make up the miRNA-29 family; miR-29b is the most highly expressed and is found at two genomic loci. Moreover, miR-29b is a multifunctional miRNA participating in different types of cancers, such as glioblastoma [6], endometrial carcinoma [7] breast cancer [8], gastric [9], ovarian [10], hepatocellular [11] and prostate [12]. However, the molecular mechanisms through which the dysregulation of miR-29b contributes to the diagnosis and prognosis of CRC remain to be further elucidated.

ETS translocation variant 4 (ETV4) is a transcription factor that shares conserved ETS DNA-binding domains, enabling it to binds to targeting gene promoter dictated by specific sequence elements bearing a conserved 5’-GGAA/T-3’ motif [13]. Its increased expression has been noted in several cancers, including colorectal, breast, ovarian, prostate, gastric, and breast [14]. A worse prognosis is linked to the overexpression of ETV4 in advanced and more aggressive tumor types [15]. Additionally, ETV4 has been linked to cancer, epithelial to mesenchymal transition, and increased motility and invasiveness [16]. Cyclin D1 is essential for cell cycle enhancement and its progression from G1- to S-phase [14]. Previous reports highlighted the mechanisms of miR-29b’s anti-oncogenic function and the genes it targets including ETV4 in experimental studies using CRC cell lines. That is why ETV4 supposed to be a new target of miR-29b [17].

The main objective of this study was to investigate the levels of miR-29b, ETV4, and cyclin D1 in CRC tissues in Egyptian patients, coupled with investigating the correlation between these markers. A further aim was to investigate the association between their levels and the clinicopathological characteristics of CRC patients.

2. Subjects and methods

This study included 80 cases of CRC; the primary diagnosis was performed in Surgery and Medical Oncology Department outpatient clinics from August 2019 to June 2021. Cases included in the study were diagnosed through a full history, clinical examination, and tests (routine CBC, liver functions, renal functions computed tomography, pelvic-abdominal ultrasonography, colonoscopy, and tissue biopsy, CEA). In this study, only patients of colon cancer of conventional type and cases with complete data and adequate biopsy material were included (Inclusion Criteria). Cases needed upfront chemotherapy and or radiotherapy and cases of special type or with inadequate biopsy material were excluded (Exclusion Criteria).

All cases of rectal cancer (15 patients) were also excluded from the study as they were not candidates for upfront surgery (need upfront chemotherapy and/or radiotherapy). After confirming the diagnosis and the workup was completed, patients were referred to the Surgery Department of Zagazig University Hospitals for suitable surgical procedures.

Sixty-five cases of colon cancer were enrolled in this work and admitted to undergo resection in the Surgery Department of Zagazig University Hospitals from August 2019 to June 2021.

At surgery time, fresh colonic tissues were taken and divided into 2 pieces. The first was frozen immediately and kept at $-$ 80C for RNA extraction. The other was preserved in 10% formalin for histopathological evaluation and further use in immunohistochemical studies. Consecutive 5- $\mu$ m thick sections from formalin-fixed, paraffin-embedded tissue blocks were prepared and stained with the Horobin and Bancroft hematoxylin and eosin (H&E) method for light microscope examination [18].

Table 1
The sequence of the different primers utilized in the study

	Forward	Reverse
miR-29b	5’-TGAACCTTTGTCTGGGCAACT-3’	5’-TGGTATCCTTGAGGGATTGGTTC-3’
ETV4	5’-CACTCCCCTACCACCATGGA-3’	5’-GGACTTGATGGCGATTTGTC-3’
U6	CGCTTCGGCAGCACATATAC	TTCACGAATTTGCGTGTCATC
GAPDH	5’-GCAAATTCCATGGCACCGT-3’	5’-TCGCCCCACTTGATT TTGG-3’

Representative sections from the tumor were taken in the Pathology Department Faculty of Medicine, Zagazig University, and the adjacent normal tissue were used as control. Specimens were evaluated for type, grade, lymphovascular invasion (LVI), tumor budding (TB), and lymph node ratio (LNR). Tumors are staged according to American Joint Committee on Cancer (AJCC) tumor node metastasis (TNM) staging system [19]. The gene expressions were done in the Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Zagazig University. Approval from the Institutional Research Board was taken by number (ZU-IRB # 9514).

The extraction of the RNA & PCR

Colonic tissues were homogenized with a power homogenizer until the disappearance of tissue clumps. From colon cancer tissues, total RNA with miRNAs extracted using the miRNeasy Mini Kit (Qiagen, Hilden, Germany). Using cDNA Synthesis Kit (iNtRON Biotechnology, Seongnam, Korea) reverse transcription of RNA wasdone. Real-time PCR was performed by Mx3005PTM (Stratagene, La Jolla, CA, USA). We follow this technique: initial denaturation and activation of polymerase for 15 min at 95 ${{}^{\circ}}$ C, then 40 cycles of denaturation for 15 sec at 94 ${{}^{\circ}}$ C; annealing for 30 sec at 55 ${{}^{\circ}}$ C; and final extension for 30 sec at 70 ${{}^{\circ}}$ C. 20 uL volume reactions were performed with 5 uL of the cDNA, 100 pmol/uL of each primer (0.5 uL each) (Biolegio, Netherlands), 10 uL of PCR EvaGreen Master Mix (Jena Bioscience GmbH, Jena, Germany) and 4 uL distilled water. The sequence of the primers utilized in the study is listed in Table 1.

MiR-29b expression was normalized to U6, while ETV4 expression was standardized to GADPH as an internal reference [17]. The cycle threshold (Ct) values were estimated. The level of expression of the studied genes was normalized by calculating the $\Delta$ Ct value. The amplitude of the expression in malignant versus the control tissues was evaluated by the 2 $-\Delta\Delta$ Ct equation.

Table 2

Demographic and clinical-pathologic characteristics of studied group

	$N=$ 65	%
Age (year):
Mean $\pm$ SD	52.55 $\pm$ 10.11
Range	25–70
Gender:
Male	39	60
Female	26	40
Size:
$<$ 5	34	52.3
$>$ 5	31	47.7
Grade:
High	42	64.6
Low	23	35.4
LVI:
Negative	40	38.5
Positive	25	61.5
TB:
High	33	50.8
Low	32	49.2
LNR:
$<$ 0.25	33	50.8
$>$ 0.25	32	49.2
LNM:
Negative	30	46.2
Positive	35	53.8
Staging:
I	8	12.3
II	22	33.8
III	33	50.8
IV	2	3.1
Cyclin D1:
Low	25	38.5
High	40	61.5
miR 29b
Mean $\pm$ SD	0.581 $\pm$ 0.116
Range	0.41–0.8
ETV4:
Mean $\pm$ SD	2.332 $\pm$ 0.18
Range	2.01–2.07
High	36	38.5
Low	29	61.5

Sd: Standard deviation.

Table 3

The association between the clinicopathological characteristics of studied colon cancer cases and miRNA 29-b

	miR29-b Median (range)	$P$	ETV4 Mean $\pm$ SD	$P$
Gender:
Male	0.73 (0.42–2.01)	0.052 ${}^{\wedge}$	2.33 $\pm$ 0.22	0.403 ${}^{\$}$
Female	0.66 (0.41–1.98)		2.37 $\pm$ 0.19
Size:
$<$ 0.5	0.684 $\pm$ 0.182	0.091 ${}^{\wedge}$	2.33 $\pm$ 0.18	0.364 ${}^{\$}$
$>$ 0.5	0.588 $\pm$ 0.171		2.38 $\pm$ 0.23
Grade:
Low	0.72 (0.42–2.01)	$<$ 0.001 ${}^{**\wedge}$	2.28 $\pm$ 0.216	0.033 ${}^{*\$}$
High	0.61 (0.41–1.99)		2.39 $\pm$ 0.187
LVI:
Negative	0.98 (0.48–2.01)	0.093 ${}^{\wedge}$	2.31 $\pm$ 0.18	0.017 ${}^{*\$}$
Positive	0.52 (0.41–0.73)		2.43 $\pm$ 0.21
TB
Low	0.7 (0.41–2.01)	0.05 ${}^{\wedge}$	2.28 $\pm$ 0.18	0.006 ${}^{*\$}$
High	0.66 (0.42–1.47)		2.42 $\pm$ 0.2
LNR:
$<$ 0.25	0.71 (0.44–2.01)	0.052 ${}^{\wedge}$	2.3 $\pm$ 0.19	0.017 ${}^{*\$}$
$>$ 0.25	0.66 (0.41–1.47)		2.41 $\pm$ 0.2
LNM:
Negative	0.71 (0.44–2.01)	0.064 ${}^{\wedge}$	2.27 $\pm$ 0.18	0.003 ${}^{*\$}$
Positive	0.67 (0.41–1.47)		2.43 $\pm$ 0.2
Staging:
I	1.46 (0.83–2.01) 2,3		2.134 $\pm$ 0.2
II	0.58 (0.41–1.73)	$<$ 0.001 ${}^{*\#}$	2.312 $\pm$ 0.141	$<$ 0.001 ${}^{**@}$
III	0.65 (0.42–0.99)		2.401 $\pm$ 0.186
IV	0.81 (0.73–0.89)		2.75 $\pm$ 0.078
Age	$r=$ 0.078	0.539	0.341	0.005 ${}^{*}$
Cyclin D1:	$r=-$ 0.341	$p$ 0.021 ${}^{*}$	$r=$ 0.372	0.002 ${}^{*}$
ETV4:	$r$ $-$ 0.286	$p$ 0.005 ${}^{*}$
miR29b			$-$ 0.248	$P=$ 0.046

${}^{\wedge}$ : $P$ value for Mann Whitney test. ${}^{\$}$ : $P$ value for independent $t$ test. ${}^{\#}$ : $P$ value for Kruskal Wallis test. ${}^{@}$ : $P$ value for ANOVA test. $r$ Spearman rank correlation coefficient. ${}^{*}p<$ 0.05 is statistically significant. ${}^{**}p\leqslant$ 0.001 is statistically highly significant.

Immunohistochemistry

Paraffin-embedded colon cancer tissues were hatched with the following antibodies: anti-ETV4 antibody (1:100; ab189826; Abcam) and anti-cyclin D1 monoclonal antibody (sc-8396, 1:80, Santa Cruz Biochemicals, CA, USA) following pressure antigen retrieval (Target Retrieval Solution, pH 6.1; Dako, Carpinteria, CA, USA). All slides examined by 2 pathologists for evaluation of immunohistochemistry stain.

The positive cells for ETV4 were counted (defined as moderate-to-strong nuclear immunoreactivity), positive nuclear expression in over 50% of the cells in the tumor was scored as high expression, while cytoplasmic expression and nuclear expression in less than 50% of the tumor cells were scored as low expression [20].

Concerning immunohistochemical staining of cyclin D1, the percentage of nuclear staining of cyclin D1 was reported as follows: 0, less than 5%; 1, 5–25%; 2, 26–50%; 3, 51–75%; and 4, more than 75%. The coloring scheme was scaled from 0 to 3, where 0 was negative, 1 was weak, 2 was moderate, and 3 was strong. The final expression score was calculated as follows: ‘ $-$ ’ for score 0, ‘ $+$ ’ for scores. 1–3, ‘ $++$ ’ for scores 4–6, and ‘ $+++$ ’ for scores $>$ 6. In order to perform statistical analysis, the cases considered low scores when taking “ $-$ ” and “ $+$ ”. In contrast, they are considered high scores if taking “ $++$ ” and “ $+++$ .” scores [21].

Data analysis was performed using the SPSS software (Statistical Package for the Social Sciences) version 28. Quantitative variables were described using their means and standard deviations or median and range according to the data type. Categorical variables were described using their absolute frequencies and compared using the chi-square test. To compare two sets of ordinal 14 data, chi-square for trend test was used. Kolmogorov-Smirnov and Levene tests were also used to verify assumptions for parametric tests. To compare quantitative data between 2 groups, the Mann-Whitney test (for not normally distributed data) was used. Moreover, the Kruskal Wallis test was used to compare not normally distributed variables within more than two groups. To assess the strength and direction of correlation between two continuous variables, Spearman rank correlation coefficients (for not normally distributed data) were used. The ROC curve was used to determine the best cutoff of certain quantitative parameters in diagnosing certain health problems. The level of statistical significance was set at P below 0.05, and a highly significant difference was present if $p\leqslant$ 0.001.

Table 4

The association between the clinicopathological characteristics of studied colon cancer cases and immunohistochemical expression of ETV4 and Cyclin D1

	Total $N=$ 65	cyclin D1			ETV4
		Low $N=$ 25 (%)	High $N=$ 40 (%)	$p$	High $N=$ 36 (%)	Low $N=$ 29 (%)	$P$
Age (year):
Mean $\pm$ SD		50.68 $\pm$ 10.4	53.73 $\pm$ 9.88	0.241 ${}^{\$}$	49.59 $\pm$ 10.66	54.94 $\pm$ 9.11	0.414 ${}^{\$}$
Gender:
Male	26 (40)	12 (46.2%)	14 (53.8%)	0.298!	12 (46.2%)	14 (53.8%)	0.222 ${}^{!}$
Female	39 (60)	13 (33.3%)	26 (66.7%)		24 (61.5%)	15 (38.5%)
Size:
$<$ 5	33 (50.8)	17 (68%)	16 (40%)	0.028 ${}^{*!}$	13 (36.1%)	20 (69%)	0.008 ${}^{*!}$
$>$ 5	32 (49.2)	8 (32%)	24 (60%)		23 (63.9%)	9 (31%)
Grade:
High	42 (64.6)	12 (28.6%)	30 (71.4%)	0.027 ${}^{*!}$	27 (64.3%)	15 (35.7%)	0.051 ${}^{!}$
Low	23 (35.4)	13 (56.5%)	10 (44.5%)		9 (39.1%)	24 (60.9%)
LVI:
Negative	40 (61.5)	23 (57.5%)	17 (42.5%)	$<$ 0.001 ${}^{*!}$	15 (37.5%)	25 (62.5%)	$<$ 0.001 ${}^{*!}$
Positive	25 (38.5)	2 (8%)	23 (92%)		21 (84%)	4 (16%)
TB:
High	33 (50.8)	1 (3%)	32 (97%)	$<$ 0.001 ${}^{*!}$	29 (87.9%)	4 (12.1%)	$<$ 0.001 ${}^{*!}$
Low	32 (49.2)	24 (75%)	8 (25%)		7 (21.9%)	25 (78.1%)
LNR:
$<$ 0.25	33 (50.8)	24 (72.7%)	9 (27.3%)	$<$ 0.001 ${}^{*!}$	8 (24.2%)	25 (75.8%)	$<$ 0.001 ${}^{*!}$
$>$ 0.25	32 (49.2)	1 (3.1%)	31 (96.9%)		28 (87.5%)	4 (12.5%)
LNM:
Negative	30 (46.2)	21 (70%)	9 (30%)	$<$ 0.001 ${}^{*!}$	7 (23.3%)	23 (76.7%)	$<$ 0.001 ${}^{*!}$
Positive	35 (53.8)	4 (11.4%)	31 (88.6%)		29 (82.9%)	6 (17.1%)
Staging:
I	8 (12.3)	8 (100%)	0 (0%)		0 (0%)	8 (100%)
II	22 (33.8)	15 (68.2%)	7 (31.8%)	$<$ 0.001 ${}^{*!}$	4 (18.2%)	18 (81.8%)	$<$ 0.001 ${}^{*!}$
III	33 (50.8)	2 (6.1%)	31 (93.9%)		30 (90.9%)	3 (9.1%)
IV	2 (3.1)	0 (0%)	2 (100%)		2 (100%)	0 (0%)
CylinD1:
Negative	25 (38.5)				4 (16%)	21 (84%)	$<$ 0.001 ${}^{**!}$
Positive	40 (61.5)				32 (80%)	8 (20%)
ETV4:
Low	36 (61.5)	4 (11.1%)	32 (88.9%)	$<$ 0.001 ${}^{**!}$	4 (16%)
High	29 (38.5)	21 (72.4%)	8 (27.6%)

${}^{\$}$ : $P$ value for independent $t$ test. ${}^{!}$ : $P$ value for Chi square ( $\chi^{2}$ ) test. ${}^{*}p<$ 0.05 is statistically significant. ${}^{**}p\leqslant$ 0.001 is statistically highly significant.

Table 5

The performance of Cyclin D1 and ETV-4 in the diagnosis of colon cancer

		Normal tissue	Colon cancer	$P^{!}$
Cyclin D1:	Low	63 (96.9%)	25 (38.5%)
	High	2 (3.1%)	40 (61.5%)	$<$ 0.001 ${}^{**}$
ETV-4	Low	61 (93.8%)	29 (44.6%)
	High	4 (6.2%)	36 (55.4%)	$<$ 0.001 ${}^{**}$
	Sensitivity	Specificity	PPV	NPV	Accuracy
High Cyclin D1	61.50%	96.90%	95.20%	71.60%	79.20%
High ETV	55.40%	93.80%	90%	67.80%	74.60%

${}^{!}$ : $P$ value for Chi square ( $\chi^{2}$ ) test. ${}^{**}p\leqslant$ 0.001 is statistically highly significant PPV positive predictive value NPV negative predictive value.

Table 6

The performance of miR29-b in the diagnosis of colon cancer

Cutoff	AUC	Sensitivity	Specificity	PPV	NPV	Accuracy	$P$
$\leqslant$ 0.965	0.833	81.5%	93.8%	98.3%	83.6%	87.7	$<$ 0.001 ${}^{**}$

Figure 1.

Immunohistochemical Expression of ETV4 in A. Normal colon (low expression with focal scattered staining x200 HPF), B. well differentiating colon cancer (low nuclear positivity), C. high grade colon cancer showing high nuclear expression of ETV4 (x400 HPF).

Figure 2.

Immunohistochemistry for cyclin D1 with different pattern A. Normal colon (no staining) (x200), B. well differentiating colon cancer (no staining), C. colon cancer (low nuclear expression), D. a case of colon cancer with high nuclear expression of Cyclin D1 (b,c,d x400 HPF).

Figure 3.

ROC curve demonstrating the validity of miRNA 29-b in the diagnosis of colon cancer.

Figure 4.

ETV4 and miRNA29b have a strong negative connection, as seen by the scatter dot.

Figure 5.

Association between cyclin D1 and miRNA29b.

3. Results

In this study, 65 patients with primary colon cancer were included; 39 males (60%) and 26 females (40%), with mean age $\pm$ SD (52.55 $\pm$ 10.11). The age ranged from 25 to 70 years. 42 patients were high grade (42%) while 23 cases (35.4%) were low grade. Among the involved cases, 35 patients (53.8%) have positive lymph node metastasis, and 32 cases (49.2%) showed LNR above 0,25 (Table 2).

MiR-29b was significantly down-regulated ( $p<$ 0.01), and ETV4 was highly significantly up-regulated ( $p<$ 0.001) in late-stage colon cancer compared to the early-stage one (Table 3). Concerning clinicopathological features, there is a statistically significant relation between miRNA 29b gene expression and both grades and staging (where the difference is significant between stage I and each of stages II and III). There is a statistically non-significant correlation between miRNA 29b and age, gender, size, LVI, TB, LNR, or LNM. There is a statistically significant relation between ETV4 gene expression and staging (where the difference is significant between stage I and each IV and III) and with grading, LVI, LNM, LNR, and TB. There is a statistically non-significant relation between ETV4 and gender.

MiR29b and ETV4 miRNA expressions had a significant negative correlation ( $r=-$ 0.248, $P=$ 0.046). (Table 3 and Fig. 4). There was also a negative relationship between miRNA 29b gene expression and cyclin D1 immune expression ( $r=-$ 0.341) and ( $p=$ 0.021) (Table 3 and Fig. 5).

Immunohistochemical expression of ETV4 (Table 4 and Fig. 1) showed statistically significant associations with high grade, LVI, LNR, TB, LVI, TILs, and advanced TNM stage.

The relationship between the immunohistochemistry of cyclin D1 with the clinicopathologic characteristics of the studied cases is presented in Table 4 and Fig. 2. The data reveal a statistically significant connection between the expression of cyclin D1 and indicators of progression in the form of LVI, LNR, TB, and TNM stages ( $P<$ 0.001).

Diagnostic role of cyclin D1 and ETV4 in colon cancer (Table 5): High cyclin D1 can diagnose colon cancer with 61.5% sensitivity, 96.9% specificity, 95.2% PPV71.6% NPV, and overall accuracy of 79.2%. High ETV can diagnose colon cancer with 93.9% sensitivity, 55.4% specificity, 67.8% PPV90% NPV, and overall accuracy of 74.6%

In colon cancer, the mean relative expression of miRNA-29b and ETV4 compared to control were (0.581 $\pm$ 0.116 and 2.332 $\pm$ 0.18) respectively. There was a significant down-regulation of miR-29b expression and a significant up-regulation of ETV4 expression in colon cancer specimens compared to control adjacent tissue specimens.

As shown in Table 6 and Fig. 3, the best miRNA 29-b cutoff for colorectal carcinoma diagnosis is 0.965, with an area under the curve of 0.833, a sensitivity of 81.5%, specificity of 93.8%, a positive predictive value of 98.3%, a negative predictive value of 83.6%, and accuracy of 87.7%.

4. Discussion

The screening methods for CRC are not easy to be used routinely. That is why many patients are undiagnosed tile the progressive stage, which affects the outcome of these patients. Colon cancer is a heterogeneous disease, and lines of therapy should be personalized. Furthermore, the increasing incidence of drug resistance among the colon cancer population supports the increasing need to find markers that help diagnose cases in the early stage and new targeted molecules [22].

The expression of miRNAs showed marked deregulation in many cancer types [23]. Their roles in various biological processes, such as cell differentiation and proliferation, have been studied [2]. Many gene expressions are under miRNAs control, post-transcriptionally, by interacting with the 3’UTR of specific target mRNAs [24]. It is hypothesized that miRNAs control cancer cell invasion and metastasis by suppressing the expression of their targets [25]. Although many researchers have studied the role of miR-29b in colon cancer, its role is still uncertain, and studying its association with ETV4 and cyclin D1 is still essential.

MiR-29b suppresses tumors by controlling oncogenes, such as T-cell leukemia/lymphoma 1 (TCL1), (Mcl-1), B-Myb, and CDC42 [26]. A previous study on CRC cell lines found a link between ETV4 expression and miR 29b [17].

First, our RT-qPCR results revealed that miR-29b expression was lower in colon cancer tissues than in nearby normal tissues. This finding was consistent with a previous study that reported decreased expression of miR-29b in colon cancer cell lines and tissue samples. They also demonstrated that miR-29b inhibits tumor growth and metastasis in colorectal cancer by down-regulating Tiam1 expression and inhibiting epithelial-mesenchymal transition [2].

Additionally, Basati et al. showed that colon cancer patients had considerably lower serum levels of miR-194 and miR-29b than control volunteers. Furthermore, the advanced TNM stages had an inverse relationship with the blood levels of the miRNAs in the patients. These findings imply that the effects of miR-29b may vary greatly depending on the target in each type of cancer and may be tumor-specific [27]. Another study found that miR-29b is typically down-regulated in colon cancer tissue, indicating that miR-29b may play a tumor-suppressive role in the emergence of colon cancer. It has been shown that miR-29b can act as a tumor suppressor to stop cancer cells from proliferating [28].

The current study reported that miR-29b expression was inversely related to the degree of TNM staging. More importantly, decreased miR-29b was associated with higher incidence of LNM, higher grade, and advanced stage in colon cancer patients.

In terms of ETV4 expression, it was detected that it is overexpressed in colon cancer. This finding was consistent with Fonseca et al. [29] and Lee et al. [30], who discovered that overexpression of ETV4 promoted colon cancer cell proliferation.

Previous experimental studies reported that knockdown of ETV4 inhibit the proliferative and invasive capacities of malignant CRC cells. Moreover, targeting of ETV4 by a certain molecule affects the downstream targets with inhibition of the ability of cancer cells to migrate and represents a future work to create a novel therapeutic strategy to treat metastatic prostate and breast cancers [30, 31].

Zeng et al. demonstrated that ETV4 regulate cell cycle genes and Wnt/catenin signalling, which was associated with an aggressive type of gastrointestinal stromal tumor [32]. Additionally, ETV4 has been linked to matrix metalloproteinase overexpression in colorectal cancer, with subsequent potentiation of invasion and cell proliferation [33]. This explains the significant correlation between ETV4 expression, LVI invasion, and metastasis capacity.

Leng et al. [17] discovered that ETV4 was a target gene of miR-29b in colon cancer cell lines. They also stated that the increased miR-29b may down-regulate ETV4 expression, and these results are consistent with the negative association between miR-29b and ETV4 miRNA expressions. These findings are intriguing because they could illuminate new mechanisms underlying miR-29b’s anti-cancer function.

Previous investigations indicated that cyclin D1 over-expression was not seen in normal mucosa, and only 15% of cases of adenoma exhibited it [21]. Similar findings were found in the current investigation since cyclin D1 expression was only present in 3.1% of the normal colonic tissue next to the tumor, strengthening its involvement in the early detection of colon cancer and supporting its contribution to the carcinogenic process.

It was noted that the overexpression of cyclin D1 was substantially correlated with grade, stage, and lymphatic vascular invasion in our study, which is consistent with prior research by Palaiologos et al. [34], who reported that no correlation between cyclin D1 and either stage or grade [21]. Thus, the etiology and metastasis of CRC are significantly influenced by the up regulation of cyclin D1. This may be explained by its regulation of the cell cycle, which disrupts the normal cell cycle and, if overexpressed, promotes the growth and spread of cancer [35].

A reverse relationship between cyclin D1 and miR-29b was found in this study. This makes sense because miR-29 controls the expression of cyclin D1, and the inhibition of the latter eliminates the cyclic pattern of cyclin D1 expression [36].

As far as the authors know, no previous studies investigated the cyclin D1 association with miR-29b in colon cancer.

The oncogenic effect of cyclin D1 occurs by controlling different substrates as Rb, the loss of Rb is consequent event for cyclin D1 mutation or amplification. Many therapeutic agents induce cyclin D1 degradation; cyclin D1 degradation by knockdown of USP2, a deubiquitylating enzyme that specifically targets cyclin D1found to inhibit the proliferation of cancer cells [37].

Although targeting cyclin D1 is difficult because it does not possess enzymatic activity, its catalytic partners CDK4/CDK6 can be targeted. As requisite functional partner kinases of cyclin D1, suppression of CDK4/CDK6 activity successfully blocks cyclin D1-mediated cell cycle progression, making these protein kinases attractive therapeutic targets [38].

5. Conclusion

Colon cancer is associated with up-regulation of ETV4, cyclin D1 overexpression and a down-regulation of miR-29b-3. Additionally, miR-29b expression was markedly reduced with progression of the tumor stage. Therefore, miR-29b expression may serve as a diagnostic indicator for early detection of colon cancer.

Author contributions

Conception: Hala Mosaad, Hanim M Abdelnour and Mona Mostafa Ahmed.

Interpretation or analysis of data: Mostafa M. Elaidy and Ola M Elfarargy.

Preparation of the manuscript: Mona Mostafa Ahmed and Hanim M Abdelnour.

Revision for important intellectual content: Mostafa M. Elaidy and Ola M Elfarargy.

Supervision: Hala Mosaad and Mai Mohamed Abdelwahab.

References

Malki

Abu ElRuz

Gupta

Allouch

Vranic

and Al Moustafa

, Molecular mechanisms of colon cancer progression and metastasis: Recent insights and advancements, International Journal of Molecular Sciences 22(1) (2020), 130.

Wang

Liu

Yang

Liao

Cui

Wang

and Zhao

, miR-29b suppresses tumor growth and metastasis in colorectal cancer via downregulating Tiam1 expression and inhibiting epithelial-mesenchymal transition, Cell Death & Disease 5(7) (2014), e1335–e1335.

Yin

Zhao

Yan

Zhou

Chen

and Wang

D.W.

, miR-320a mediates doxorubicin-induced cardiotoxicity by targeting VEGF signal pathway, Aging (Albany NY) 8(1) (2016), 192.

Cervigne

N.K.

Reis

P.P.

Machado

Sadikovic

Bradley

Galloni

N.N.

Pintilie

Jurisica

Perez-Ordonez

Gilbert

et al., Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma, Hum Mol Genet 18(24) (2009), 4818–4829.

Peng

and Croce

, The role of MicroRNAs in human cancer, Signal Transduction and Targeted Therapy 1(1) (2016), 1–9.

Cortez

M.A.

Nicoloso

M.S.

Shimizu

Rossi

Gopisetty

Molina

J.R.

Carlotti

Jr Tirapelli

et al., miR-29b and miR-125a regulate podoplanin and suppress invasion in glioblastoma, Genes, Chromosomes and Cancer 49(11) (2010), 981–990.

Chen

Wang

Jin

Zheng

Lin

Zhang

et al., MiR-29b-3p promotes chondrocyte apoptosis and facilitates the occurrence and development of osteoarthritis by targeting PGRN, Journal of Cellular and Molecular Medicine 21(12) (2017), 3347–3359.

Chou

Lin

J.H.

Brenot

Kim

J.W.

Provot

and Werb

, GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression, Nature Cell Biology 15(2) (2013), 201–213.

Gong

Wang

Liu

Jia

Jiang

et al., Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer, Carcinogenesis 35(2) (2014), 497–506.

10.

Flavin

Smyth

Barrett

Russell

Wen

Wei

et al., miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma, International Journal of Gynecologic Cancer 19(4) (2009).

11.

Fang

J.H.

Zhou

H.C.

Zeng

Yang

Liu

Huang

et al., MicroRNA-29b suppresses tumor angiogenesis, invasion, and metastasis by regulating matrix metalloproteinase 2 expression, Hepatology 54(5) (2011), 1729–1740.

12.

Steele

Newhall

Phillips

N.J.

Toth

and Ray

R.B.

, miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling, Molecular Cancer Therapeutics 11(5) (2012), 1166–1173.

13.

Kar

and Gutierrez-Hartmann

, Molecular mechanisms of ETS transcription factor mediated tumorigenesis, Crit. Rev. Biochem. Mol. Biol. 48 (2013), 522–543.

14.

Tyagi

Deshmukh

S.K.

Srivastava

S.K.

Azim

Ahma

Ahmed

A.G.

Singh

A.P.

et al., ETV4 Facilitates Cell-Cycle Progression in Pancreatic Cells through Transcriptional Regulation of Cyclin D1Role of ETV4 in Pancreatic Cancer Pathogenesis, Molecular Cancer Research 16(2) (2018), 187–196.

15.

Liu

Shen

Wang

Zeng

Wang

et al., Overexpression of ETV4 is associated with poor prognosis in prostate cancer: Involvement of uPA/uPAR and MMPs, Tumor Biology 36 (2015), 3565–3572.

16.

Pellecchia

Pescucci

L.E.

Luceri

Passaro

SicaM

et al., Overexpression of ETV4 is oncogenic in prostate cells through promotion of both cell proliferation and epithelial to mesenchymal transition, Oncogenesis 1(7) (2012), e20–e20.

17.

Leng

Chen

Ding

Zhao

Qin

and Pan

, Overexpression of microRNA-29b inhibits epithelial-mesenchymal transition and angiogenesis of colorectal cancer through the ETV4/ERK/EGFR axis, Cancer Cell International 21 (2021), 1–19.

18.

Horobin

R.W.

and Bancroft

J.D.

, Trouble Shooting Histology Stains, Chapter (22), Churchill living stone, 1998: 88–93.

19.

Amin

M.B.

Greene

F.L.

Edge

S.B.

Compton

C.C.

Gershenwald

J.E.

Brookland

R.K.

Meyer

Gress

D.M.

Byrd

D.R.

and Winchester

D.P.

, The eighth edition AJCC cancer staging manual: Continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging, CA: A Cancer Journal for Clinicians 67(2) (2017), 93–99.

20.

Wang

Ding

Liu

Chang

Shen

Xie

S.M.

Xing

and Li

, ETV4 overexpression promotes progression of non-small cell lung cancer by upregulating PXN and MMP1 transcriptionally, Molecular Carcinogenesis 59(1) (2020), 73–86.

21.

Albasri

A.M.

Elkablawy

M.A.

Ansari and

I.A.

and Alhujaily

A.S.

, Prognostic significance of Cyclin D1 over-expression in colorectal cancer: An experience from Madinah, Saudi Arabia, Asian Pacific Journal of Cancer Prevention: APJCP 20(8) (2019), 2471.

22.

Zhai

Yang

Zhang

and Sun

, Colorectal cancer heterogeneity and targeted therapy: Clinical implications, challenges and solutions for treatment resistance, Seminars in Cell & Developmental Biology, Vol. 64. Academic Press, 2017.

23.

Serpico

Molino

and Di Cosimo

, microRNAs in breast cancer development and treatment, Cancer Treatment Reviews 40(5) (2014), 595–604.

24.

Ivey

K.N.

and Srivastava

, microRNAs as developmental regulators, Cold Spring Harbor Perspectives in biology 7(7) (2015), a008144.

25.

Chan

S.H.

and Wang

L.H.

, Regulation of cancer metastasis by microRNAs, Journal of Biomedical Science 22(1) (2015), 1–12.

26.

Martinez

Cazalla

Almstead

L.L.

Steitz

J.A.

and DiMaio

, miR-29 and miR-30 regulate B-Myb expression during cellular senescence, Proceedings of the National Academy of Sciences 108(2) (2011), 522–527.

27.

Basati

Razavi

A.E.

Pakzad

and Malayeri

F.A.

, Circulating levels of the miRNAs, miR-194, and miR-29b, as clinically useful biomarkers for colorectal cancer, Tumor Biology 37 (2016), 1781–1788.

28.

Yan

Guo

F.J.

Wang

Yin

Wei

Y.B.

and Yang

J.R.

, The role of miR-29b in cancer: regulation, function, and signaling, OncoTargets and therapy, 2015: 539–548.

29.

Fonseca

A.S.

Ramao

Bürger

M.C.

de Souza

J.E.S.

Zanette

D.L.

de Molfetta

G.A.

et al., ETV4 plays a role on the primary events during the adenoma-adenocarcinoma progression in colorectal cancer, BMC Cancer 21(1) (2021), 1–14.

30.

Lee

J.S.

Kim

Lee

Kim

et al., Capicua suppresses colorectal cancer progression via repression of ETV4 expression, Cancer Cell International 20 (2020), 1–11.

31.

Butler

M.S.

Hsing

Roshan Moniri

Lau

Yen

Kim

Lien

Mroczek

Ghaidi

LeBlanc

and McIntosh

, Targeting ETS factor ETV4 as a novel therapeutic for the management of breast and prostate cancer, Cancer Research 75(15_Supplement) (2015), 1648–1648.

32.

Zeng

Seifert

A.M.

Zhang

J.Q.

Kim

T.S.

Bowler

T.G.

Cavnar

M.J.

Medina

B.D.

Vitiello

G.A.

Rossi

Loo

J.K.

and Param

N.J.

, ETV4 collaborates with Wnt/β-catenin signaling to alter cell cycle activity and promote tumor aggressiveness in gastrointestinal stromal tumor, Oncotarget 8(69) (2017), 114195.

33.

Nosho

Yoshida

Yamamoto

Taniguchi

Adachi

Mikami

Hinoda

and Imai

, Association of Ets-related transcriptional factor E1AF expression with overexpression of matrix metalloproteinases, COX-2 and iNOS in the early stage of colorectal carcinogenesis, Carcinogenesis 26 (2005), 892–899.

34.

Palaiologos

Chrysikos

Theocharis

and Kouraklis

, The prognostic value of G1 cyclins, p21 and Rb protein in patients with colon cancer, Anticancer Research 39(11) (2019), 6291–6297.

35.

Cunningham

Atkin

Lenz

H.J.

Lynch

H.T.

Minsky

Nordlinger

et al., Colorectal cancer, Lancet 375 (2010), 1030–1047. doi: 10.1016/S0140-6736(10)60353-4.

36.

Beezhold

Klei

L.R.

and Barchowsky

, Regulation of cyclin D1 by arsenic and microRNA inhibits adipogenesis, Toxicology Letters 265 (2017), 147–155.

37.

Musgrove

E.A.

Caldon

C.E.

Barraclough

Stone

and Sutherland

R.L.

, Cyclin D as a therapeutic target in cancer, Nature Reviews Cancer 11(8) (2011), 558–572.

38.

Qie

and Diehl

J.A.

, Cyclin D1, cancer progression, and opportunities in cancer treatment, Journal of Molecular Medicine 94 (2016), 1313–1326.

Down-regulated MiRNA 29-b as a diagnostic marker in colorectal cancer and its correlation with ETV4 and Cyclin D1 immunohistochemical expression

Abstract

BACKGROUND:

OBJECTIVES:

METHODS:

RESULTS:

CONCLUSION:

Keywords

Abbreviations

1. Introduction

2. Subjects and methods

Table 1 The sequence of the different primers utilized in the study

The extraction of the RNA & PCR

Immunohistochemistry

4. Discussion

5. Conclusion

Author contributions

References

Table 1
The sequence of the different primers utilized in the study